NCT05088161

Brief Summary

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 13, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 23, 2021

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 21, 2021

Completed
22 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 12, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 12, 2022

Completed
Last Updated

October 21, 2021

Status Verified

October 1, 2021

Enrollment Period

6 months

First QC Date

June 23, 2021

Last Update Submit

October 19, 2021

Conditions

Patients

Outcome Measures

Primary Outcomes (1)

  • Differentially expressed proteins in tumor and paracancer tissues

    Two dimensional gel electrophoresis, mass spectrometry and other techniques were used to separate and compare pancreatic cancer tissues and normal adjacent tissues to search for differentially expressed proteins.

    180 Days

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The subjects in this study were all patients with pathologically diagnosed pancreatic cancer.

You may qualify if:

  • Patients of Chinese nationality, age and gender are not limited.
  • Pathologically confirmed pancreatic cancer patients.
  • Pathological specimens were archived tumor tissue samples after a diagnosis of pancreatic cancer.
  • Clinical diagnostic information was complete three months before sampling.

You may not qualify if:

  • Patients with a second primary tumor.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Phase I Clinical Research Center

Qingdao, Shandong, 266003, China

RECRUITING

Study Officials

  • Yu Cao, Doctor

    the study director of phase I clinical research center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yu Cao, Doctor

CONTACT

86-18661809090caoyu1767@126.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 23, 2021

First Posted

October 21, 2021

Study Start

May 13, 2021

Primary Completion

November 12, 2021

Study Completion

March 12, 2022

Last Updated

October 21, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)